Axsome Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 18, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
(a)
- Consolidated Financial Statements
The following consolidated financial statements of Axsome Therapeutics, Inc. are filed as part of this report.
| Contents | Page |
|---|---|
| Reports of Independent Registered Public Accounting Firm (PCAOB ID: 34) (PCAOB ID: 42) | F-1 |
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Operations for the Years Ended December 31, 2024, 2023, and 2022 | F-6 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended December 31, 2024, 2023, and 2022 | F-7 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2024, 2023, and 2022 | F-8 |
| Notes to the Consolidated Financial Statements | F-9 |
- Consolidated Financial Statement Schedules
The financial statement schedule entitled “Schedule II – Valuation and Qualifying Accounts” has been omitted since the information required is included in the consolidated financial statements and notes thereto. Other schedules are omitted because they are not applicable, or the required information is shown in the Financial Statements or notes thereto.
- Exhibits
The list of exhibits filed with this report is set forth in the Exhibit Index following the signature page and is incorporated herein by reference.
Index to Consolidated Financial Statements
| Page | |
| Reports of Independent Registered Public Accounting Firm | F-1 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-5 |
| Consolidated Statements of Operations for the years ended December 31, 2024, 2023, and 2022 | F-6 |
| Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2024, 2023, and 2022 | F-7 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023, and 2022 | F-8 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.